CoChat

The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003

Eliasson, B., Cederholm, J., Nilsson, P., Gudbjörnsdóttir, S., for the Steering Committee of the Swedish National Diabetes Register · 2005 · Diabetic Medicine
Cited by 130

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Guidelines for the treatment of risk factors in diabetes care have been updated recently, due to indisputable results from clinical end‐point trials. This study evaluates risk factor control compared with current national and international targets during the period 1996–2003 in Type 2 diabetes (DM2). Patients were registered in primary‐care and hospital outpatient clinics using computer software, or via the Internet. The clinical characteristics of the patients, treatment, HbA 1c, and risk factors were reported after screening by local methods. The numbers of cases of DM2 reported were 17547 in 1996 and 57119 in 2003. The mean HbA 1c decreased from 7.8 to 7.2%, while blood pressure decreased from 150/82 to 143/78 mmHg during the same period. Longitudinal analysis of results was performed in 5356 patients repeatedly reported, showing slightly lower effects. The new European treatment targets of HbA 1c≤ 6.1%, blood pressure < 130/80 mmHg and total cholesterol < 4.5 mmol/l were attained by 16, 13 and 28% of the patients in 2003, respectively. The prevalence of the metabolic syndrome in 2003 was 77%. Aspirin was prescribed in 36% of cases. Lipid‐lowering, anti‐hypertensive drugs, and treatment with oral hypoglycaemic agents in combination with insulin were increasingly employed during the period studied. Risk factor control in DM2 reported to the National Diabetes Register (NDR) is slowly improving, although multiple risk factors and the metabolic syndrome are found in most patients. The majority of subjects do not achieve current target levels for HbA 1c, blood pressure and blood lipids. Thus, giving up smoking and increased use of aspirin are called for, as well as more aggressive treatment of hyperglycaemia, elevated blood pressure and blood lipid levels, in accordance with updated international guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01648.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 130

Metadata

Authors
Eliasson, B., Cederholm, J., Nilsson, P., Gudbjörnsdóttir, S., & for the Steering Committee of the Swedish National Diabetes Register
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-09-13
Volume
22
Issue
10
Pages
1420-1426
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2112250427
Cited by
130
References
9
FWCI
9.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01648.x
The paper
Eliasson, B., Cederholm, J., Nilsson, P., Gudbjörnsdóttir, S., & for the Steering Committee of the Swedish National Diabetes Register. (2005). The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01648.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.